Revance Therapeutics Inc. (RVNC)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
RVNC Chart
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
RVNC Shareholders with Large Losses are Encouraged to Seek Counsel to Lead the Revance Therapeutics, Inc. Class Action - Contact Robbins LLP Today
SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Revance Therapeutics, Inc. (NASDAQ:RVNC) securities between February 29, 2024 and December 6, 2024. Revance is a biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the U.S. and internationally.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc.(RVNC) Shareholders
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Revance Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| KLM Kevin L. Mccreless CONCOURSE FINANCIAL GROUP SECURITIES Inc. | 570 | $2.8 | - | -$2.8 | -100% |
 Guillaume Binnendijk Cigogne Management SA | 111,825 | $339,948 | $339,948 | - | - |
Revance Therapeutics Inc. (RVNC) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Revance Therapeutics Inc. Profile
| - Industry | - Sector | Mr. Mark J. Foley CEO | NASDAQ (NMS) Exchange | 761330109 CUSIP |
| US Country | 597 Employees | - Last Dividend | - Last Split | 6 Feb 2014 IPO Date |
Overview
Revance Therapeutics, Inc. is an innovative biotechnology firm focused on the development, manufacture, and commercialization of neuromodulators for a variety of aesthetic and therapeutic applications, both within the United States and on a global scale. Originally founded in 1999 under the name Essentia Biosystems, Inc., the company underwent a rebranding to Revance Therapeutics, Inc. in April 2005. Headquartered in Nashville, Tennessee, Revance is committed to advancing the field of neuromodulation through its research and product development. Its collaborative efforts with Viatris Inc. to develop and commercialize certain products underscore its strategic approach to bringing novel therapies to market.
Products and Services
- DAXXIFY (DaxibotulinumtoxinA-lanm) for Injection:
This leading drug candidate by Revance is designed for the treatment of glabellar lines (frown lines between the eyebrows) and cervical dystonia (a painful condition where neck muscles contract involuntarily, causing abnormal head position). DAXXIFY has completed phase II clinical trials for additional applications, including upper facial lines, dynamic forehead lines, lateral canthal lines (crow’s feet), adult upper limb spasticity, and plantar fasciitis.
- OnabotulinumtoxinA (Biosimilar to BOTOX):
A biosimilar product to the well-known BOTOX, OnabotulinumtoxinA is currently in the preclinical stage of development at Revance. This product signifies the company’s efforts to expand its portfolio in the competitive neuromodulators market by offering alternatives to established brands.
- Resilient Hyaluronic Acid (RHA) Dermal Filler:
Revance offers RHA dermal fillers for the correction of moderate to severe dynamic facial wrinkles and folds. These advanced fillers are designed to adapt to the dynamics of facial movements, providing a natural-looking result that maintains efficacy with facial motion.
- RHA Redensity:
An extension of the RHA line, RHA Redensity is specifically formulated for the treatment of moderate to severe dynamic perioral rhytids (wrinkles around the mouth). This product demonstrates Revance’s commitment to addressing a wide range of aesthetic concerns with innovative solutions.
